nference
Under the multiyear strategic partnership Anumana will conduct a clinical-validation trial and seek FDA De Novo classification for the algorithm.
NeuTrace focused on developing in-procedure AI tools for electrophysiology.
nference said researchers can use the de-identified clinical data to develop new therapeutics and diagnostics.
The partnership will focus on software that uses ECGs to find left ventricular dysfunction and atherosclerotic cardiovascular disease.